The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / From the Expert: New Advances in Treatment of Systemic Scleroderma

From the Expert: New Advances in Treatment of Systemic Scleroderma

April 22, 2016 • By Richard Quinn

  • Tweet
  • Email
Print-Friendly Version / Save PDF

lungs_BSIP-SA_Alamy_500x270Systemic scleroderma (SSc) is “arguably the most challenging illness” rheumatologists encounter, according to Aryeh Fischer, MD, associate professor of medicine, Division of Rheumatology, Division of Pulmonary Sciences and Critical Care Medicine, at the University of Colorado School of Medicine in Denver.

You Might Also Like
  • 2014 ACR/ARHP Annual Meeting: Fibrotic Complications of Scleroderma
  • Treatment Tips for Pulmonary Arterial Hypertension & ILD
  • A Deep-Dive Discussion with the Author of a Systemic Scleroderma Study
Also By This Author
  • 2016 ACR Distinguished Fellows Award Winners Discuss Early Career Contributions to Rheumatology

Dr. Fischer, who served as a co-investigator in the Scleroderma Lung Study II (SLS II), expects “significant expansion” of therapeutic options in the coming years.1 He spoke to The Rheumatologist about the results of the study, which were published as an abstract at the 2015 ACR/ARHP Annual Meeting.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Question: What is the biggest challenge interstitial lung disease (ILD) poses in SSc patients?
Answer: The ILD portion in SSc is particularly challenging in that available therapies are so limited. Even with treatment, the best we have to offer is stability or [the] mild improvement of ILD.

Q: What are your initial thoughts on the study results?
A: This study validated current clinical practice and gave stronger support for the use of mycophenolate mofetil (MMF) for the treatment of SSc-ILD. SLS I showed that oral cyclophosphamide (CYC) can mildly improve lung function and CT-evidence of fibrosis, and is associated with improved [quality of life].2 But CYC is not a long-term option and is often not well tolerated. Based on a growing body of retrospective data, clinical practice patterns have changed over the past five or so years. MMF has replaced CYC in many centers or is, at least, a very common first-line agent for autoimmune ILD, in general, and SSc-ILD, in particular. With [the] SLS II results, we now have more robust evidence to substantiate that practice pattern. I suspect this will lead only to more use of MMF as first-line therapy in autoimmune ILD, in general, and SSc-ILD in particular.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Q: The study abstract cites a number of conclusions. Which are most practical for clinicians?
A: The most relevant to me are that:

  1. MMF is as effective as CYC for SSc-ILD;
  2. MMF is far better tolerated than CYC;
  3. MMF is a good long-term option; and
  4. CYC is an effective agent for SSc-ILD, but is limited to short-term usage.

Q: Any other links between the first and second studies?
A: Both studies prove that CYC is an effective drug for this disease. In practice, because many practitioners prefer the IV route due to a better safety profile, CYC remains a good—albeit a shorter-term—option for this disease.

Q: Why is it important to look at these treatments?
A: SLS I and II, and the FAST study have been landmark trials because they are the first to successfully implement randomized, placebo-controlled—except for SLS II—trials looking to establish whether current options are effective for this disease.3 Ultimately, we need to explore novel, therapeutic options in this domain. Fortunately, those studies are underway in various phases, and without question, many more are to follow.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Pages: 1 2 | Single Page

Filed Under: Conditions, Scleroderma Tagged With: cyclophosphamide, Interstitial Lung Disease, lung, mycophenolate mofetil, Scleroderma, systemic scleroderma

You Might Also Like:
  • 2014 ACR/ARHP Annual Meeting: Fibrotic Complications of Scleroderma
  • Treatment Tips for Pulmonary Arterial Hypertension & ILD
  • A Deep-Dive Discussion with the Author of a Systemic Scleroderma Study
  • Stem Cell Transplantation Shown to Improve Outcomes in Systemic Sclerosis

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)